Vigonvita Life Sciences Announces Inadvertent Use and Full Redemption of IPO Proceeds; Implements Remedial Actions
Vigonvita Life Sciences Co., Ltd. (Stock Code: 2630) has released a supplemental announcement regarding the inadvertent use of funds sourced from its recent Global Offering (IPO proceeds). The company has also outlined comprehensive remedial measures and confirmed the incident’s resolution, with implications that shareholders and investors should carefully consider.
Key Points from the Announcement
- Inadvertent Use of IPO Proceeds: In January 2026, Vigonvita Life Sciences subscribed to two unlisted market funds with independent third parties, totaling HK\$51,124,000. The first subscription of HK\$35,124,000 was funded by company funds. However, the second subscription of HK\$16,000,000 was mistakenly funded using net proceeds from the company’s Global Offering (IPO proceeds), contrary to the stated use of funds.
- Cause of the Incident: The error was due to an oversight by the finance department, which failed to notice insufficient company funds in the relevant account and mistakenly believed, based on the company prospectus, that the subscription fell within permitted uses of IPO proceeds.
- Immediate Rectification: Upon discovery, the company took immediate action and has confirmed that the entire HK\$16,000,000 second subscription has been fully redeemed.
Shareholder-Relevant and Potentially Price Sensitive Information
- Compliance and Regulatory Issues: The incident involved a temporary non-compliance with the intended use of IPO proceeds as disclosed in the company’s prospectus and could raise concerns about internal control and governance lapses.
- Remedial Measures: The company has implemented several remedial actions, including:
- Mandatory legal and compliance training for finance, accounting personnel, responsible staff, senior management, and directors.
- Regular quarterly and bi-annual training sessions covering disclosure obligations, risk management, and transaction protocols.
- Upgraded approval mechanisms in its Office Automation (OA) system for transactions over RMB 2,000,000, requiring finance department checks to ensure sufficient company funds and proper use of IPO proceeds.
- Mandatory consultation with compliance advisor and joint company secretaries before purchasing wealth management products.
- No Ongoing Impact on Use of IPO Proceeds: The company has reaffirmed that all IPO proceeds will be used strictly according to the original and intended purposes as disclosed in the prospectus.
- Disclosure and Transparency: The incident and its resolution have been disclosed in the company’s annual report for the year ended December 31, 2025, and confirmed in this supplemental announcement.
- Transaction Classification: Both fund subscriptions and subsequent redemptions are not classified as discloseable transactions under the Hong Kong Listing Rules, as the size thresholds were not met and the fund managers involved are independent from each other.
Implications for Shareholders and Investors
- The incident reveals a temporary lapse in internal controls, which could raise investor concerns about corporate governance and risk management at Vigonvita Life Sciences. However, the company’s prompt rectification and comprehensive remedial actions may help restore confidence.
- The full redemption of the mistakenly used IPO proceeds ensures there is no ongoing financial impact from the incident. The company’s commitment to enhanced compliance and transparency is a positive signal for long-term governance improvements.
- No direct financial loss occurred due to the error, and the company has taken steps to prevent recurrence.
- Shareholders should monitor future disclosures and the effectiveness of the company’s new internal controls and training programs.
Current Board Composition
As of June 1, 2026, the Board comprises Dr. Tian Guanghui (Chairman, Executive Director, CEO, and General Manager), Dr. Hu Tianwen (Executive Director), Mr. Liu Haoxuan (Non-executive Director), and independent non-executive Directors Dr. Ju Dianwen, Ms. Cao Xinwen, and Dr. Xu Hongxi.
Disclaimer: This article provides a summary and analysis of the supplemental announcement issued by Vigonvita Life Sciences Co., Ltd. Investors should refer to official company disclosures and consult professional advisors before making investment decisions. The information provided is not intended as investment advice.
維健維他生命科學補充公告：意外動用IPO資金及已全面補救措施
維健維他生命科學有限公司（股份代號：2630）發佈補充公告，披露其近期全球發售（IPO）所得資金被意外動用事件，並詳細說明已採取的補救措施及事件進展，投資者及股東需特別留意。
公告重點
- IPO資金意外動用：2026年1月，維健維他認購兩隻與獨立第三方有關的非上市市場基金，共涉資港幣51,124,000元。當中首筆港幣35,124,000元由公司自有資金支付，第二筆港幣16,000,000元則因財務部門疏忽，錯誤動用了IPO募集所得資金，並不符招股書所載用途。
- 事件原因：財務部門當時未有察覺相關賬戶自有資金不足，全因誤信招股書容許此類用途，導致出錯。
- 即時糾正：公司發現後即時展開退還程序，現已確認全數港幣16,000,000元已贖回。
對股東及可能影響股價的重要資訊
- 合規及監管風險：事件涉及一段時間內違反IPO資金用途承諾，或引發投資者對公司內控及管治的憂慮。
- 補救措施：公司已即時採取多項補救行動，包括：
- 法律顧問為財會人員、相關職員、高層及董事提供培訓，加強對《證券及期貨條例》第XIVA部及上市規則第14章的認識。
- 每季定期培訓財會人員，半年為高層培訓，董事則每年一次，內容涵蓋披露義務、風險管理及內部報批流程。
- OA系統升級，涉及人民幣200萬元或以上交易前，須自動提交財務部門審批，確保資金來源合規。
- 日後購買理財產品前，必須預先徵詢合規顧問及公司秘書意見。
- IPO資金用途無受持續影響：公司重申所有IPO資金最終只會按招股書所披露用途使用。
- 資訊披露及透明度：事件及其解決過程已於2025年年報及本補充公告中全面披露。
- 交易分類：兩項基金認購及贖回均未達上市規則須披露交易門檻，且基金經理互不關聯。
對投資者的啟示
- 事件反映公司內部監控曾一度失誤，或令市場關注其企業管治及風險管理水平。然而，公司迅速糾正並推行多項補救措施，有望恢復市場信心。
- IPO資金全數追回，未造成實際經濟損失，公司亦承諾加強合規及透明度，屬正面信號。
- 建議股東密切留意公司往後披露及新內控措施成效。
現時董事會成員
截至2026年6月1日，董事會成員包括：田光輝博士（董事會主席、執行董事、行政總裁及總經理）、胡天文博士（執行董事）、劉浩軒先生（非執行董事）、以及獨立非執行董事鞠殿文博士、曹欣雯女士及徐洪熙博士。
免責聲明：本文僅為維健維他生命科學有限公司補充公告之摘要及分析。投資者應參閱公司正式公告及諮詢專業人士，切勿視本資料為投資建議。
